0000000000639837

AUTHOR

Piero Maestrelli

showing 2 related works from this author

Upregulation of basic fibroblast growth factor in smokers with chronic bronchitis

2006

The aim of the study was to investigate the expression of basic fibroblast growth factor (bFGF) and its receptor, fibroblast growth factor receptor (FGFR)-1, in the central airways of smokers with chronic bronchitis. The lobar bronchi from 17 subjects undergoing thoracotomy for solitary nodules were examined. All had a history of cigarette smoking, nine had symptoms of chronic bronchitis and airflow limitation, and eight were asymptomatic with normal lung function. Using immunohistochemical methods, bFGF and FGFR-1 expression in the total airway wall and the different airway compartments, i.e. bronchial glands, submucosal vessels and smooth muscle, was quantified. Moreover, to investigate t…

MalePulmonary and Respiratory MedicinePathologymedicine.medical_specialtyChronic bronchitisAngiogenesisBasic fibroblast growth factorFibroblast growth factorchemistry.chemical_compoundGrowth factor receptorCigarette smokingHumansMedicineAgedFibrolast growth factor receptor-1business.industryChronic obstructive pulmonary diseaseFibroblast growth factor receptor 1Smokingrespiratory systemmedicine.diseaseAirway remodelling; cigarette smoking; chronic obstructive pulmonary disease; fibroblast growth factor receptor-1Airway remodellingUp-Regulationrespiratory tract diseasesBronchitis ChronicchemistryFibroblast growth factor receptorBronchitisFemaleFibroblast Growth Factor 2Airway remodelling; Chronic obstructive pulmonary disease; Cigarette smoking; Fibrolast growth factor receptor-1;business
researchProduct

Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe…

2021

Background: ANDHI was done to assess the efficacy of benralizumab, including onset of effect and impact on health-related quality of life (HRQOL), exacerbation rate, lung function, and nasal polyposis symptoms. Methods: This phase 3b, randomised, double-blind, parallel-group, placebo-controlled ANDHI study was completed in adults (aged 18–75 years) with severe eosinophilic asthma with at least 2 exacerbations in the previous year, despite high-dose inhaled corticosteroid plus additional controllers, screening blood eosinophil counts of at least 150 cells per μL, and an Asthma Control Questionnaire 6 (ACQ-6) score of 1·5 or more. Patients who met eligibility criteria were randomly assigned (…

Pulmonary and Respiratory MedicineSpirometryAdultMalemedicine.medical_specialtyExacerbation[SDV]Life Sciences [q-bio]PopulationSettore MED/10 - Malattie Dell'Apparato RespiratorioPlaceboAntibodies Monoclonal Humanized03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDouble-Blind MethodInternal medicinemedicineHumans030212 general & internal medicineAnti-Asthmatic AgentsPatient Reported Outcome MeasureseducationSinusitisAsthmaeducation.field_of_studymedicine.diagnostic_testbusiness.industryMiddle Agedmedicine.diseaseBenralizumabAsthma3. Good healthEosinophils030228 respiratory systemchemistryAsthma Control QuestionnaireSpirometryDisease ProgressionQuality of LifeFemalebusiness
researchProduct